J. Easton

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.

The paper investigates RA's limited effect on primary neuroblastoma tumors but efficacy in clearing bone marrow cells, identifying BMP signaling as a key determinant of cell fate and RA sensitivity.

Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma

This study creates two mouse models with conditional c-MYC activation in specific cell types, leading to distinct neuroendocrine tumors resembling human neuroblastoma and somatostatinoma.

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs.

The paper compares mesenchymal-like gene expression programs in neuroblastoma preclinical models and patient tumors using single-cell RNA-seq and identifies chemotherapy-induced changes in PDX and GEMM.

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization

This study shows NSD2 E1099K mutation disrupts 3D chromatin organization in B-ALL, leading to drug resistance and clonal evolution through compartmentalization changes.

A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis

This study identifies a neonatal liver niche that promotes hepatoblastoma metastasis via the Cxcl1/Cxcr2 axis, showing increased tumor aggressiveness and hypoxia in early postnatal models.

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

miR-424(322) is a molecular switch controlling pro-inflammatory vs anti-inflammatory skin DC subset differentiation by modulating TGF-β signaling

This study identifies miR-424(322) as a molecular switch that controls the differentiation of pro-inflammatory monocyte-derived DCs (moDCs) versus anti-inflammatory Langerhans cells (LCs) by modulating TGF-β signaling.

MYCN Amplification and ATRX Mutations are Incompatible in Neuroblastoma

The paper shows that ATRX mutations and MYCN amplification are mutually exclusive in neuroblastoma and lead to synthetic lethality.

Genome-wide Segregation of Single Nucleotide and Structural Variants into Single Leukemia Cells

The paper introduces a method to analyze single-cell variants in leukemia, finding structural variations precede single nucleotide changes in cancer development.